Alterity Therapeutics Limited

NASDAQ:ATHE

Biotechnology

Healthcare
$3.12 +9.89%

+$0.53 today

Market cap
$52.77M
Beta
-0.03
P/E (TTM)
-9.9
EPS (TTM)
-$0.07
52W Low $2.66High $7.00

Volume 0.02M

Average 0.05M

ATHE EBITDA Margin

EBITDA as a percentage of revenue.

Alterity Therapeutics LimitedNASDAQ: ATHE

EBITDA Margin · Q2 FY2026 · quarter ended Dec 2025

EBITDA Margin not reported for Q2 FY2026

Over 3 fiscal years it widened by 70.4 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 6 analysts of -315.9% for the fiscal year ending Jun 2026, down from -269.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
—— QoQ
Last fiscal yearJun 2025
-269.0%+217.9 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year+217.9 pp-46.9 pp-264.8 pp
3 years+70.4 pp+97.9 pp+27.5 pp
5 years+238.9 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-269.0%
Year-over-year change
+217.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ATHE compares with its peers on the latest reported figures

  • ATHE's FY2025 EBITDA Margin of -269.0% is the lowest of the 2 companies compared; the peer median is -230.3%.
  • Its year-over-year change of +217.9 pp is the highest of 2, against a peer median of -71.7 pp.
  • Over three fiscal years its change of +70.4 pp compares with a peer median of -215.4 pp.
ATHE Competitors Peer median
EBITDA Margin for ATHE and competitors
Company Period LTM level YoY 3-year change
DYAIDyadic International, Inc.LTM Mar 2026-230.3% -71.7 pp-215.4 pp
ATHEAlterity Therapeutics LimitedFY2025-269.0% +217.9 pp+70.4 pp
MAIAMAIA Biotechnology, Inc.FY2025— ——
ANVSAnnovis Bio, Inc.FY2025— ——
Peer median (excluding ATHE) -230.3%-71.7 pp-215.4 pp

Competitors are the stored peer set for ATHE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

AUD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue4.34M5.12M3.92M4.02M5.44M
Cost of Revenue360.03K364.67K285.07K214.3K127.52K
Gross Profit3.98M4.76M3.63M3.8M5.31M
Gross Margin91.7%92.9%92.7%94.7%97.7%
Research & Development12.28M14.75M13.2M18.64M14.4M
Selling, General & Admin6.87M5.51M5.04M4.76M5.48M
Operating Expenses19.16M20.26M18.24M23.41M19.89M
Depreciation & Amortization18.66K54.21K37.85K35.34K28.31K
EBITDA(15.16M)(17.39M)(14.6M)(19.57M)(14.63M)
EBITDA Margin-349.3%-339.5%-372.8%-486.9%-269.0%
Operating Income(15.18M)(15.5M)(14.64M)(19.6M)(14.57M)
Operating Margin-349.8%-302.6%-373.7%-487.7%-268.0%
Interest Income20.68K2.5K16.44K268.42K446.29K
Interest Expense00000
Other Income / Expenses(133.04K)2.72M904.68K524.33K2.49M
Income Before Tax(15.31M)(12.78M)(13.7M)(19.08M)(12.08M)
Pre-Tax Margin-352.8%-249.4%-349.9%-474.6%-222.1%
Income Tax Expense(3.08M)70.01K104.46K46.09K68.06K
Net Income(15.31M)(12.85M)(13.81M)(19.12M)(12.15M)
Net Margin-352.8%-250.7%-352.5%-475.8%-223.4%
EPS (Basic)(5.40)(3.18)(3.42)(3.12)(1.14)
EPS (Diluted)(5.40)(3.18)(3.42)(3.12)(1.14)
Weighted Avg Shares2.83M4.01M4.05M6.08M10.66M
Weighted Avg Shares (Diluted)2.83M4.01M4.05M6.08M10.66M

Alterity Therapeutics Limited

NASDAQ:ATHE

Intrinsic Alpha fair value

Locked

Current Price

$3.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.